News
What we have published, filed and advanced.
2026
First-in-human report published, peer reviewed
A translational mechanistic and first-in-human therapeutic report on our lead cardiovascular mechanism appears in a peer-reviewed journal, open access.
Read the paper, open access →2026
Composition patent filed on our IL-17 program
A first-in-class IL-17 small molecule generated by QRGenAI, with its own intellectual property position.
June 2026
Technical submission to the FDA
QR Genetics submitted a technical comment to the agency’s initiative on drug repurposing for unmet medical needs, describing the platform, its evidence base and its approach to human-first therapeutic discovery.
Docket FDA-2026-N-4492 on regulations.gov →